Page 1046 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 3

59. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of 75. Menendez R, Martinez R, Reyes S, et al. Biomarkers improve
procalcitonin-guided treatment on antibiotic use and outcome mortality prediction by prognostic scales in community-
in lower respiratory tract infections: cluster-randomised, single- acquired pneumonia. Thorax. 2009;64(7):587-591.
blinded intervention trial. Lancet. 2004;363(9409):600-607. 76. Ramirez P, Ferrer M, Marti V, et al. Inflammatory bio-
60. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guid- markers and prediction for intensive care unit admission
ance of antibiotic therapy in community-acquired pneumonia: a in severe community-acquired pneumonia. Crit Care Med.
randomized trial. Am J Respir Crit Care Med. 2006;174(1):84-93. 2011;39(10):2211-2217.
61. Cuquemelle E, Soulis F, Villers D, et al. Can procalcitonin help 77. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association
identify associated bacterial infection in patients with severe between pneumococcal pneumonia and acute cardiac events.
influenza pneumonia? A multicentre study. Intens Care Med. Clin Infect Dis. 2007;45(2):158-165.
2011;37(5):796-800.
78. Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial
62. Don M, Valent F, Korppi M, et al. Efficacy of serum procalcito- infarction in hospitalized patients with community-acquired
nin in evaluating severity of community-acquired pneumonia pneumonia. Clin Infect Dis. 2008;47(2):182-187.
in childhood. Scand J Infect Dis. 2007;39(2):129-137.
79. Moammar MQ, Ali MI, Mahmood NA, DeBari VA, Khan MA.
63. Restrepo MI, Mortensen EM, Rello J, Brody J, Anzueto A. Late Cardiac troponin I levels and alveolar-arterial oxygen gradient
admission to the ICU in patients with community-acquired in patients with community-acquired pneumonia. Heart Lung
pneumonia is associated with higher mortality. Chest. 2010; Circ. 2010;19(2):90-92.
137(3):552-557.
80. Christ-Crain M, Breidthardt T, Stolz D, et al. Use of B-type
64. Renaud B, Santin A, Coma E, et al. Association between timing natriuretic peptide in the risk stratification of community-
of intensive care unit admission and outcomes for emergency acquired pneumonia. J Intern Med. 2008;264(2):166-176.
department patients with community-acquired pneumonia.
Crit Care Med. 2009;37(11):2867-2874. 81. Leroy O, Saux P, Bedos JP, Caulin E. Comparison of levofloxacin
and cefotaxime combined with ofloxacin for ICU patients with
65. Renaud B, Labarere J, Coma E, et al. Risk stratification of early community-acquired pneumonia who do not require vasopres-
admission to the intensive care unit of patients with no major sors. Chest. 2005;128(1):172-183.
criteria of severe community-acquired pneumonia: development
of an international prediction rule. Critical Care. 2009;13(2):R54. 82. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG,
Coalson JJ, Anzueto A. Impact of macrolide therapy on mortal-
66. Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool ity for patients with severe sepsis due to pneumonia. Eur Respir J.
for predicting the need for intensive respiratory or vasopressor 2009;33(1):153-159.
support in community-acquired pneumonia. Clin Infect Dis.
2008;47(3):375-384. 83. Rodriguez A, Mendia A, Sirvent JM, et al. Combination antibiotic
therapy improves survival in patients with community-acquired
67. Lim WS, van der Eerden MM, Laing R, et al. Defining com- pneumonia and shock. Crit Care Med. 2007;35(6):1493-1498.
munity acquired pneumonia severity on presentation to hos-
pital: an international derivation and validation study. Thorax. 84. Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination
2003;58(5):377-382. antibiotic therapy with macrolides improves survival in intu-
bated patients with community-acquired pneumonia. Intens
68. Niederman MS, Bass JB Jr, Campbell GD, et al. Guidelines for
the initial management of adults with community-acquired Care Med. 2010;36(4):612-620.
pneumonia: diagnosis, assessment of severity, and initial anti- 85. Mykietiuk A, Carratala J, Fernandez-Sabe N, et al. Clinical out-
microbial therapy. Am Rev Respir Dis. 1993;148(5):1418-1426. comes for hospitalized patients with Legionella pneumonia in
69. Brown SM, Jones BE, Jephson AR, Dean NC. Validation of the antigenuria era: the influence of levofloxacin therapy. Clin
the Infectious Disease Society of America/American Thoracic Infect Dis. 2005;40(6):794-799.
Society 2007 guidelines for severe community-acquired pneu- 86. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The impact
monia. Crit Care Med. 2009;37(12):3010-3016. of empiric antimicrobial therapy with a beta-lactam and fluo-
70. Espana PP, Capelastegui A, Quintana JM, et al. A prediction rule roquinolone on mortality for patients hospitalized with severe
to identify allocation of inpatient care in community-acquired pneumonia. Crit Care. 2005;10(1):R8.
pneumonia. Am J Respir Crit Care Med. 2003;21(4):695-701. 87. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial
71. Rello J, Rodriguez A, Lisboa T, Gallego M, Lujan M, Wunderink antibiotic choice on clinical outcomes in community-acquired
R. PIRO score for community-acquired pneumonia: a new pneumonia: analysis of a hospital claims-made database. Chest.
prediction rule for assessment of severity in intensive care unit 2003;123(5):1503-1511.
patients with community-acquired pneumonia. Crit Care Med. 88. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients
2009;37(2):456-462. with 2009 H1N1 influenza in the United States, April-June
72. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy 2009. N Engl J Med. 2009;361(20):1935-1944.
in the treatment of severe sepsis and septic shock. N Engl J Med. 89. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-
2001;345(19):1368-1377. course levofloxacin for community-acquired pneumonia: a new
73. Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients treatment paradigm. Clin Infect Dis. 2003;37(6):752-760.
at low risk of death from community-acquired pneumonia 90. Shorr AF, Zadeikis N, Xiang JX, Tennenberg AM, Wes Ely E. A
across all CRB-65 classes. Eur Respir J. 2008;31(2):349-355. multicenter, randomized, double-blind, retrospective compari-
74. Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with son of 5- and 10-day regimens of levofloxacin in a subgroup of
procalcitonin and clinical rules in community-acquired pneu- patients aged > or = 65 years with community-acquired pneu-
monia. Ann Emerg Med. 2008;52(1):48-58. e42. monia. Clin Ther. 2005;27(8):1251-1259.

Section05-O-ref.indd 3 1/20/2015 4:51:18 PM